Alexion Pharmaceuticals Inc ALXN:NASDAQ

Last Price$101.88NASDAQ Closing Price as of 4:00PM ET 8/10/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-1.40(1.36%)
Bid (Size)$101.57 (2)
Ask (Size)$102.00 (1)
Day Low / High$101.11 - 103.66
Volume1.8 M
 

View Biotechnology IndustryPeer Comparison as of 08/10/2020

 

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $101.88
Change: -1.40 (1.36%)
Volume: 1.8 M
4:00PM ET 8/10/2020
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $118.25
Change: -0.42 (0.35%)
Volume: 785.3 K
4:00PM ET 8/10/2020
 
 

Incyte Corp ( NASDAQ )

Price: $94.32
Change: -2.61 (2.69%)
Volume: 1.2 M
4:00PM ET 8/10/2020
 
 

Seattle Genetics Inc ( NASDAQ )

Price: $157.70
Change: -2.75 (1.71%)
Volume: 913.7 K
4:00PM ET 8/10/2020
 
 

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $138.57
Change: -4.96 (3.46%)
Volume: 533.5 K
4:00PM ET 8/10/2020
 

Read more news Recent News

2020 and 2021 Estimates for Alexion Pharmaceuticals Targeted Higher but Q3 Earnings Number Reduced
11:50PM ET 7/31/2020 MT Newswires

Alexion Pharmaceuticals Inc's (NASDAQ:ALXN, Recent Price: 102.49) forecasted earnings estimates for Q3 ending September 30, 2020, and the full year...

--Analyst Actions: William Blair Downgrades Alexion Pharmaceuticals to Market Perform From Outperform
12:56PM ET 7/31/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Analyst Actions: Raymond James Cuts Alexion Pharmaceuticals' Price Target to $151 From $156, Keeps at Outperform
11:03AM ET 7/31/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Analyst Actions: Wedbush Lifts Price Target on Alexion Pharmaceuticals to $156 From $142, Maintains Outperform
9:16AM ET 7/31/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionAlexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. View company web site for more details
Address121 Seaport Boulevard
Boston, Massachusetts 02210
Phone+1.475.230.2596
Number of Employees2,656
Recent SEC Filing07/31/2020S-8
Chief Executive Officer & DirectorLudwig N. Hantson
President & DirectorAradhana Sarin
Chief Commercial, Global Operations Officer & EVPBrian M. Goff
Executive VP, Head-Research & DevelopmentJohn J. Orloff

Company Highlights

Price Open$103.10
Previous Close$103.28
52 Week Range$72.67 - 125.52
Market Capitalization$22.3 B
Shares Outstanding219.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement10/28/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings27.61
Earnings per Share$10.41
Beta vs. S&P 500N/A
Revenue$4.1 B
Net Profit Margin15.40%
Return on Equity7.71%

Analyst Ratings as of 07/30/2020

Buy
10
Overweight
3
Hold
9
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset